Data from a U.S. Phase II trial showed that in 14 patients receiving Chronocort, overnight cortisol profiles were closer to the normal physiological profile than in those receiving conventional, immediate-release hydrocortisone. The majority of Chronocort-...

PQS began an open-label, crossover, U.S. Phase II trial (Study 004) in 12 patients to compare once-daily Chronocort vs. thrice-daily immediate-release hydrocortisone. Patients will receive a minimum of 7 days of the immediate-release version followed...

In 1Q08, PQS expects to begin a double-blind, European and U.S. Phase III trial (Study 006) in about 250 patients to evaluate corticosteroids plus either Chronocort or standard of care. Phoqus Group plc (LSE:PQS), West...

In 1Q08, PQS expects to begin an open-label, European and U.S. Phase III trial (Study 005) in about 60 to evaluate corticosteroids plus either Chronocort or standard treatment. Phoqus Group plc (LSE:PQS), West Malling, U.K....

This month, PQS will begin an open-label, U.S. Phase II trial (Study 004) in 130 patients to evaluate corticosteroids plus either Chronocort or standard of care. NIH will sponsor the trial. Phoqus Group plc (LSE:PQS),...

Novartis has launched a new venture fund, the $200 million Novartis Option Fund , which will give the pharmaceutical company a first option to license a very early stage program at portfolio companies. "As I...

The university spun out Absynth Biologics Ltd. (Sheffield, U.K.), which will use the university’s antibody-recognition technology to develop vaccines and antibodies against S. aureus, including methicillin-resistant S. aureus (MRSA). BFN, which invested £325,000 ($637,000) in...